Get the Stockscreener App
169.19
6.78%
-12.31
After Hours:
169.19
Icon Plc stock is traded at $169.19, with a volume of 1.62M.
It is down -6.78% in the last 24 hours and up +16.32% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$181.50
Open:
$180.05
24h Volume:
1.62M
Relative Volume:
1.04
Market Cap:
$13.66B
Revenue:
$8.19B
Net Income/Loss:
$758.19M
P/E Ratio:
18.43
EPS:
9.18
Net Cash Flow:
$1.06B
1W Performance:
-13.24%
1M Performance:
+16.32%
6M Performance:
-15.01%
1Y Performance:
-48.49%
1-Day Range:
$168.57
$181.59
1-Week Range:
$168.57
$194.00
52-Week Range:
$125.10
$331.53
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
169.19 | 14.12B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
467.68 | 180.17B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
197.16 | 146.07B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
534.31 | 46.01B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.81 | 33.53B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.86 | 32.56B | 15.50B | 1.33B | 2.16B | 7.34 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
ICON Plc’s Earnings Call: Balancing Achievements and Challenges - TipRanks
ICON plc: Initiation of Coverage- Capitalizing On Opportunities in China, A Critical Growth Market! - smartkarma.com
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape By Investing.com - Investing.com India
ICON plc’s SWOT analysis: navigating challenges in CRO stock landscape - Investing.com
Icon PLC (ICLR) Q2 Report: Barclays Raises Price Target to $180, Maintains Equal Weight Rating - AInvest
ICON plc Reports Strong Q2 2025 Financial Results - The Globe and Mail
ICON plc Expands Share Repurchase Program and Resumes COVID Vaccine Study - The Globe and Mail
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $209 to $240 - 富途牛牛
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Wins By GuruFocus - Investing.com Canada
Icon PLC (ICLR) Q2 2025 Earnings Call Highlights: Navigating Cha - GuruFocus
Icon plc's Shares Surge 17.2% Amid Investor Optimism - AInvest
Icon Plc Announces Kedrion IVIg 10% Study for Chronic ITP: Market Implications - AInvest
ICON Expects $8B in Revenue for Full Year, Driven by Biotech Wins and Pharma Partnerships - AInvest
ICON plc Announces Successful AGM Resolutions - The Globe and Mail
ICON’s Unexpected Surge: What’s Behind the Jump? - timothysykes.com
ICON Stock Up After Q2 Results Signal Growing Confidence In Biopharma Recovery - Benzinga
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $170 to $224 - 富途牛牛
Icon plc (ICLR) Shares Surge Over 17% Amid Investor Optimism | ICLR Stock News - GuruFocus
Icon Plc’s New Study on Kedrion IVIg 10% for Chronic ITP: What Investors Need to Know - TipRanks
ICON’s Earnings Beat and Strategic Moves: A Market Outlook - StocksToTrade
RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On ThursdayArrive AI (NASDAQ:ARAI), ASGN (NYSE:ASGN) - Benzinga
Growth or Bubble? Decoding the Rapid Rise of ICLR Stock - StocksToTrade
Icon PLC Q2 Earnings Exceed Projections with $183 Million ProfitNews and Statistics - IndexBox
S&P 500 Futures Climb in Premarket Trading; West Pharmaceutical Svcs, Icon PLC Lead - Barron's
ICON: Lower Guidance Downside & Expanded Repurchase Plan (ICLR) - Seeking Alpha
Icon PLC: Q2 Earnings Snapshot - CTPost
ICON Announces Results of Annual General Meeting - BioSpace
ICON PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Icon PLC (ICLR) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
ICON plc Reports Strong Q2 2025 Financial Results and Updates Guidance - TipRanks
ICON PLC earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
SUI Insider Grant: President Gets 4,788 Restricted Shares at $125.06 | ICLR SEC FilingForm 6-K - Stock Titan
ICON Reports Second Quarter 2025 Results | ICLR Stock News - GuruFocus
ICON's Resilience in a Turbulent Market: A Case for Strategic Investment - AInvest
ICON Announces Results of Annual General Meeting | ICLR Stock News - GuruFocus
ICON Reports Second Quarter 2025 Results - Business Wire
ICON plc Stock Takes Center Stage. What’s Next? - StocksToTrade
ICON plc’s Market Surge: Examining Strong Moves - timothysykes.com
ICON plc Emerges as Phase 1 Clinical Trials Leader in New Benchmark Report - StocksToTrade
ICON plc Emerges as Top Contender in Clinical Research Arena - timothysykes.com
Icon (ICLR) Shares Surge Over 14% to Reach $160 | ICLR Stock New - GuruFocus
ICON PLC expected to post earnings of $3.21 a shareEarnings Preview - TradingView
Icon ICLR 2025Q2 Earnings Preview Downside Risk Amid Macroeconomic Issues and Trial Delays - AInvest
Analysts Estimate Icon PLC (ICLR) to Report a Decline in Earnings: What to Look Out for - MSN
ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly - 富途牛牛
Medical Device Regulatory Affairs Market Key Players Analysis - openPR.com
Do You Believe in the Upside Potential of ICON PLC (ICLR)? - MSN
Launch Your Career as a Life Science Intern at ICON, Apply Now! - BioTecNika
ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report - Lelezard
ICON’s Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report - Business Wire
Clinical Trial Investigative Site Network Market Top Players - openPR.com
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):